GURUFOCUS.COM » STOCK LIST » Creative Antibiotics AB (OSTO:CAS) » Definitions » Debt-to-Revenue

Creative Antibiotics AB (OSTO:CAS) Debt-to-Revenue : N/A (As of Mar. 2013)


View and export this data going back to . Start your Free Trial

What is Creative Antibiotics AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Creative Antibiotics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2013 was kr0.00 Mil. Creative Antibiotics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2013 was kr0.00 Mil. Creative Antibiotics AB's annualized Revenue for the quarter that ended in Mar. 2013 was kr0.00 Mil.


Creative Antibiotics AB Debt-to-Revenue Historical Data

The historical data trend for Creative Antibiotics AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Creative Antibiotics AB Debt-to-Revenue Chart

Creative Antibiotics AB Annual Data
Trend Jun08 Jun09 Jun10 Dec11
Debt-to-Revenue
- - - N/A

Creative Antibiotics AB Quarterly Data
Jun08 Mar09 Jun09 Sep09 Dec09 Mar10 Sep10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Mar13
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - N/A

Competitive Comparison of Creative Antibiotics AB's Debt-to-Revenue

For the subindustry, Creative Antibiotics AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creative Antibiotics AB's Debt-to-Revenue Distribution in the Industry

For the industry and sector, Creative Antibiotics AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Creative Antibiotics AB's Debt-to-Revenue falls into.



Creative Antibiotics AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Creative Antibiotics AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2011 is calculated as

Creative Antibiotics AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2013 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2013) Revenue data.


Creative Antibiotics AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Creative Antibiotics AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Creative Antibiotics AB (OSTO:CAS) Business Description

Traded in Other Exchanges
N/A
Address
Website

Creative Antibiotics AB (OSTO:CAS) Headlines

From GuruFocus

Cascade Acquisition Corp. Announces Liquidation

By GuruFocusNews GuruFocusNews 05-28-2022

Cascade Acquisition Corp. Announces Liquidation

By GuruFocusNews GuruFocusNews 06-27-2022

Cascade Acquisition Corp. Announces Liquidation

By GlobeNewswire GlobeNewswire 05-18-2022

Cascade Acquisition Corp. Announces Liquidation

By GuruFocusNews GuruFocusNews 06-17-2022

Cascade Acquisition Corp. Announces Liquidation

By GuruFocusNews GuruFocusNews 07-07-2022

Cascade Acquisition Corp (CAS.U) CEO Jay N. Levine Bought $2.5 million of Shares

By GuruFocus Research GuruFocus Editor 11-27-2020

Cascade Acquisition Corp. Announces Liquidation

By GuruFocusNews GuruFocusNews 06-07-2022